Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo–targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20Low tBregs. Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B–expressing cytolytic CD8+ T cells, offering some explanative power for the effect. These findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo. Cancer Res; 73(7); 2127–38. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“As a result, the increase in myeloid and myeloid-derived suppressor cells (MSC and MDSC) and regulatory T cells (Tregs) is often a sign of poor disease outcome in both mice and humans with cancer (1-3).”
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574 · cited 1×
“Protection from autoimmune diseases in mice and humans is shown to be mediated by unique subsets of Bregs (the definition first used by Mizoguchi (4)), such as murine IL-10 -producing B10 and B1b Bregs (4, 5); human IL-10 producing memory CD24CD27 B-cells (6), CD25 CD27 CD86 CD1d B cells (7), and CD19CD24CD38 B cells…”
BackgroundDing, Q., Yeung, M., Camirand, G., Zeng, Q., Akiba, H., Yagita, H., Chalasani, G., Sayegh, M. H., Najafian, N., & Rothstein, D. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46274 · Cited by 462 · cited 1×
“tBregs differ from the immune tolerance-inducing IL-10-producing Bregs and B cells (24-26).”
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449 · cited 2×
“Targeted delivery of CpG-ODN to CXCR5-expressing cells abrogates lung metastasis by inhibiting tBregs and activating B cells to promote antigen-specific CD8þ T cells Because systemic injections of free CpG-ODN can promote lymphoid follicle destruction and immunosuppression (35), to circumvent this potential problem, w…”
Cited by
B cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Influence of Resveratrol on the Immune Response
Malaguarnera, L. (2019) · Nutrients · doi:10.3390/nu11050946 · Cited by 526
Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
Wang, S.-S., Liu, W., Ly, D., Xu, H., Qu, L., & Zhang, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0027-x · Cited by 524
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
“Furthermore, evidence from mouse studies suggest that anti-CD20 depletion can impair T cell-mediated antitumor immunity [79] and even promote cancer escape, because Bregs evoked by the tumor often express CD20 at low levels [80].”
Metadata
- Authors
- Bodogai, M., Lee Chang, C., Wejksza, K., Lai, J., Merino, M., Wersto, R. P., Gress, R. E., Chan, A. C., Hesdorffer, C., & Biragyn, A.
- Venue
- Cancer Research
- Published
- 2013-04-01
- Volume
- 73
- Issue
- 7
- Pages
- 2127-2138
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2112660477
- Cited by
- 136
- References
- 4
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-4184
- The paper
- Bodogai, M., Lee Chang, C., Wejksza, K., Lai, J., Merino, M., Wersto, R. P., Gress, R. E., Chan, A. C., Hesdorffer, C., & Biragyn, A. (2013). Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-4184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.